Savage Brian
Known title: Interim Chief Legal OfficerCIK: 0002112339
Associated companies
this person other insiders at TEVA
Transaction History
| TEVA | ▲ Buy | Option Exercise | 4,503 | $156K | 9/18/2026 | View on chart |
| TEVA | ▼ Sell | Open Market | 4,503 | $174K | 9/18/2026 | View on chart |
| TEVA | ▼ Sell | Open Market | 2,525 | $99K | 9/18/2026 | View on chart |
| TEVA | ▼ Sell | Open Market | 314 | $12K | 9/18/2026 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 3,580 | — | 3/5/2026 | View on chart |
| TEVA | ▼ Sell | Open Market | 1,127 | $36K | 3/5/2026 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 4,744 | — | 3/4/2026 | View on chart |
| TEVA | ▼ Sell | Open Market | 1,489 | $48K | 3/4/2026 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 3,466 | — | 3/4/2026 | View on chart |
| TEVA | ▼ Sell | Open Market | 1,186 | $39K | 3/4/2026 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 3,461 | — | 3/3/2026 | View on chart |
| TEVA | ▼ Sell | Open Market | 1,274 | $41K | 3/3/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Teva Receives FDA Approval for Weltruza, Announces R&D Day
Teva Pharmaceutical Industries secured FDA approval for Weltruza, a once‑monthly long‑acting injectable for schizophrenia. The approval follows the company’s announcement of an R&D day in New York City, where it will discuss its pipeline and future research plans. Barclays raised its price target to $47, citing the new product launch and potential growth in the schizophrenia market. These developments add fresh catalysts to Teva’s outlook.
Teva Receives FDA Approval for Weltruza, Announces R&D Day. Teva Pharmaceutical Industries secured FDA approval for Weltruza, a once‑monthly long‑acting injectable for schizophrenia. The approval follows the company’s announcement of an R&D day in New York City, where it will discuss its pipeline and future research plans. Barclays raised its price target to $47, citing the new product launch and potential growth in the schizophrenia market. These developments add fresh catalysts to Teva’s outlook.